BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20601791)

  • 1. Seroprotection after hepatitis B vaccination in chronic kidney disease patients with modified schedule and dosage.
    Siddiqui S; Malik A; Shukla I; Rizvi M; Haque SF
    J Infect Dev Ctries; 2010 Jun; 4(6):389-92. PubMed ID: 20601791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
    Jafarzadeh A; Zarei S; Shokri F
    Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
    Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
    Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccination against hepatitis B in patients with chronic renal failure--twenty years follow-up].
    Roznovský L; Tvrdík J; Kabieszová L; Petrousová L; Orságová I; Hozáková L; Lochman I; Kloudová A; Valkovský I; Letocha P; Schwarzová S; Hladík M; Zjevíková A
    Vnitr Lek; 2011 Oct; 57(10):808-14. PubMed ID: 22097688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
    Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
    Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.
    Tung J; Carlisle E; Smieja M; Kim PT; Lee CH
    Am J Kidney Dis; 2010 Oct; 56(4):713-9. PubMed ID: 20630640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders.
    Lin C; Zhu J; Zheng Y; Chen Y; Wu Z; Chong Y; Gao Z
    J Infect; 2010 Apr; 60(4):264-70. PubMed ID: 20138189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine].
    Moulia-Pelat JP; Spiegel A; Excler JL; Martin P; Roux JF; Boutin JP; Blondeau C; Saliou P
    Sante; 1996; 6(1):11-5. PubMed ID: 8612008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a hepatitis B vaccination schedule with two cycles of four double doses of conventional vaccine and four doses of adjuvanted vaccine in chronic kidney disease patients evaluated for renal transplantation.
    García-Agudo R; Aoufi Rabih S; Araque Torres P; Dolores Fraga Fuentes M; Carlos Valenzuela Gámez J; Mancha Ramos J; María Tenías Burillo J
    Transplant Proc; 2012 Nov; 44(9):2532-4. PubMed ID: 23146445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of maternal and fetal hepatitis B antibody titers following maternal vaccination in pregnancy.
    Ingardia CJ; Kelley L; Lerer T; Wax JR; Steinfeld JD
    Am J Perinatol; 1999; 16(3):129-32. PubMed ID: 10438194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to hepatitis B vaccination in high risk population.
    Prakash C; Bhatia R; Kumari S; Verghese T; Datta KK
    J Commun Dis; 2000 Mar; 32(1):17-21. PubMed ID: 11129560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to hepatitis B vaccine in end-stage renal disease patients.
    Chow KM; Law MC; Leung CB; Szeto CC; Li PK
    Nephron Clin Pract; 2006; 103(3):c89-93. PubMed ID: 16534237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.